Orexo's AmorphOX Pivot: From Commercial Pharma to Nasal Powder Platform

After the Zubsolv divestiture, Orexo is betting on its AmorphOX delivery platform and a renewed partnering push to unlock value.

ORX.ST · Earnings Call · 2026-07-16

The Clean Slate

Orexo's Q2 2026 report is a study in contrast: while the market fixates on tariffs and macro, this small Swedish pharma (market cap ~SEK 672M) is executing a deliberate transformation. "We have continued to clean up the company and going through the transformation after the sale of Zubsolv in the end of last year," said CEO Nikolaj Sørensen. The divestiture of Zubsolv U.S. has left a leaner P&L, with CFO Fredrik Järrsten guiding to normalized OpEx of approximately SEK 60 million per quarter (excluding one-time items like the GAIA settlement), annualizing to about SEK 240 million. Cash stood at SEK 233 million after accounting for the SEK 44 million payable to Dexcel. The negative cash flow of -SEK 98 million from continued operations is largely tied to rebase payments from the legacy Zubsolv business, set to phase out by year-end.

The AmorphOX Platform Takes Center Stage

The real shift is strategic. Orexo is no longer just a developer of its own drugs; it's positioning AmorphOX platform as a delivery technology to license. The company announced a scientific collaboration with an external pharma to explore AmorphOX for GLP-1 agonists: "We are also, during the quarter, we started what we can call an early-stage scientific collaboration with an external pharmaceutical company to basically work out with the AmorphOX application to GLP-1 agonist." This validates the platform's potential beyond internal programs. Sørensen highlighted the platform's advantages—thermostability, eliminating cold chain, and extended shelf life—which are particularly compelling for vaccine companies seeking nasal delivery. The recent recruitment of a new Head of Business Development signals a more aggressive partnering push, with multiple ongoing discussions across vaccines and the GLP 1 agonist space.

The DOJ Overhang

The Department of Justice investigation has been a persistent overhang, but the tone has shifted. "We have intensified our discussions with the U.S. Department of Justice," said Sørensen. Management now expects a settlement with payments spread over several years, partly covered by insurance—a clear departure from earlier, more guarded language.

It's something where I think there's a very constructive dialogue with the DOJ for what is feasible for Orexo to ensure that we can continue our operations.
Nikolaj Sørensen, CEO · 2026-07-16

This resolution is critical: it would remove a major uncertainty and unlock financing options. In response to an analyst question on raising equity, Sørensen noted "we would need more clarity around the DOJ before we can do that," underlining the overhang's impact on capital flexibility.

Near-Term Catalysts

The pipeline is maturing. Izipry, the opioid overdose rescue, is on track to file in September, with potential approval in early 2027—a milestone that will intensify partnering efforts, as management noted in the prior call: "We will start the process now when we ... we will intensify the efforts to see what we can do with IZIPRY." OX640, the nasal epinephrine for anaphylaxis, will start a nasal allergy challenge study in Q4, with a pivotal program costing around SEK 200 million from today to filing. The company is actively seeking partners for both products, with OX640 positioned globally. The OX390 project for xylazine overdose continues with BARDA support; as previously explained, it targets a distinct need because "naloxone does not have a beneficial effect on the respiratory depression associated with xylazine." These catalysts are well-defined but the financial runway is limited, making the success of the partnering strategy key.

The Broader Context

While the global tape is dominated by tariff and geopolitical themes, Orexo's story is idiosyncratic. It's a micro-cap with a unique delivery platform that could appeal to larger pharma seeking differentiation. The keyword trajectories show a clear pivot: new attention on nasal formulation as a versatile tool, and the market may not yet be pricing in the platform value. The next quarters will be telling, as the Izipry filing, OX640 trial start, and the GLP-1 in vivo study results arrive in quick succession. For investors, the question is whether the DOJ settlement and platform partnerships can transform this small-cap into a credible licensing story.